// App-Quantinova.ai

1382 : Single Dose Alemtuzemab Provides Comparable Rejection Free and Infection Free Survival Compared to Double Dose Alemtuzumab. In Comparison to Alemtuzemab, Basiliximab Has Superior Infection Free Graft Survival. Results from a Steroid Sparing Transplant Group

Researchers

Presenter

  • H. Sharma

Principal Investigators

  • A. Odugoudar

  • B. Devkaran

  • A. Rao

  • A. El-Bakry

  • T. Gunawardhane

  • D. Ridgway

  • M. Howse

  • S. Mehra

Medical Centers

  • Department of Gastroenterology, University of Liverpool, Liverpool, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Alemtuzumab

  • Basiliximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved